In this dataset, the term covers liquid biologic formulations, typically monoclonal antibodies, concentrated enough to raise solution viscosity, promote self-association, or cause opalescence during storage. Claims in scope address the excipients, process steps such as ultrafiltration, and stability-testing methods used to make such a formulation viable for subcutaneous injection. The search string used to build this corpus specifically combines high-concentration and viscosity terms with excipient and stability terms, which distinguishes it from broader biologics formulation filings that do not address concentration-driven viscosity.

The ranking covers 100 companies, with the leading assignee holding 150 records, fifth place at 93 records and tenth place at 69 records. The top five filers combined account for 31.1% of the 2,067 records in scope, and the top ten reach 48.3% — meaningful concentration, but with over half the corpus held by companies outside the leading ten. This mix of large pharmaceutical companies and smaller specialist filers suggests the field is still open to new entrants with a focused filing programme.

Filing activity plateaued rather than grew or declined in the most recent complete years: 148 filings in 2021 against 149 in 2024, a flat +1% change. The peak year so far was 2022 at 166 filings. Years after 2024 in the trend chart appear lower, but that reflects the roughly 18-month lag between filing and publication rather than a genuine drop in activity, so those final years should not be read as a slowdown.